In past few years drug delivery has become a significant factor in improving the quality of life. Syringes and injectors have evolved substantially to cater to changing clinical and patient demands. The appearance and easy usability of disposable drug injectors has created opportunity for auto injector drug manufacturers as they offer many advantages over traditional methods.
Epinephrine (Adrenaline) auto-injectors are latest trend in the market and are used for the treatment of anaphylaxis which occurs in people suffering from cardiac arrest, allergy and asthma. Epinephrine is a colorless clear sterile solution also called as adrenaline. These auto injectors are the basic treatment for treating anaphylaxis which enables non medical people to treat the disorder effectively. Delayed administration may increase the risk .of death. The drug enables to reverse symptoms of an allergic reaction by opening airways, accelerating the heart rate and maintaining the blood pressure. They are available as pre filled auto injecting devices that contain the drug to be injected under the skin or into the muscle along the outer side of the thigh. Currently, there are two Epinephrine auto-injectors available Anapen and Epipen and they are classified as S3 drugs that allow them to be bought from a pharmacy without a prescription. Anapen has a considerably longer shelf life as compared to Epipen.
Administering an injection by a non medical person poses risk and challenges. The use of an auto injector can benefit the healthcare professional and user in many ways such as reduced anxiety, ease in self administering the drug, improved safety etc. In addition, auto injectors offer business benefits such as meet customer needs, meet legislative requirements etc.
Global Epinephrine Auto-injector market has been growing rapidly. One major driver for this market growth has been the increasing ubiquity of allergies amongst people. Therefore, increase in number of patients allergic to dust, insect bites and venom, food and food additives, has driven the market growth. Furthermore, investments by vendors in Research & Development activities to develop Chlorofluorocarbon-free epinephrine auto-injector inhalers using hydrofluoroalkane propellant instead have also accelerated the market growth. Adverse side effects such as cardiac arrhythmia, pulmonary edema, vomiting, cerebral hemorrhage etc as a result of excessive epinephrine usage can pose to be a challenge to the market.
The key participants in this market include Amedra Pharmaceuticals LLC, Mylan Inc, ALK Abello, Sanofi SA, and Lincoln Medical Ltd. Other vendors include Itelliject Inc, Adamis Pharmaceuticals Corp, Hospira Inc, Teva Pharmaceuticals Ltd and Antares Pharma Inc.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.